Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a strong sell rating to a sell rating in a research report released on Saturday.

A number of other research analysts have also weighed in on the stock. HC Wainwright cut their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Finally, Canaccord Genuity Group started coverage on Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Structure Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Structure Therapeutics Stock Down 2.9%

NASDAQ:GPCR opened at $48.04 on Friday. The company’s 50 day moving average is $46.51 and its 200-day moving average is $55.25. Structure Therapeutics has a 12 month low of $15.80 and a 12 month high of $94.90. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -55.22 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. Research analysts predict that Structure Therapeutics will post -1.64 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP increased its holdings in shares of Structure Therapeutics by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after purchasing an additional 1,432,797 shares during the period. Avoro Capital Advisors LLC lifted its stake in shares of Structure Therapeutics by 21.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after buying an additional 1,150,000 shares during the period. Janus Henderson Group PLC grew its position in Structure Therapeutics by 5.2% during the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after buying an additional 264,833 shares in the last quarter. BVF Inc. IL grew its position in Structure Therapeutics by 8.6% during the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock worth $241,966,000 after buying an additional 275,105 shares in the last quarter. Finally, Morgan Stanley increased its stake in Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares during the period. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.